Atopic Dermatitis
Digital Education Hubs
CME Virtual Symposium / Webcasts
Slides
2025
Getting Handy: CHE, Contact Derm, Palmar Hyperhidrosis, and Warts
Elizabeth Swanson, MD
Biologics in Pediatric Atopic Dermatits
Shivani Patel, MD
Updated on Systemic JAK Inhibitors for Atopic Dermatits
Robert Sidbury MD, MPH
Environmental Impact on Atopy
Peter Lio, MD
Latest Updates and Expert Recommendations in Treating Atopic Dermatitis
Emma Guttman-Yassky, MD, PhD and Shawn G. Kwatra, MD
JAK Inhibitors in Atopic Dermatitis
Christopher G. Bunick, MD, PhD
2024
Distinguishing Chronic Hand Eczema:
All Hands on Deck
Christopher Bunick, MD, PhD,
and Jonathan Silverberg, MD, PhD, MPH
Skirting Steroids in AD: New and Emerging Non-Steroidal Topical Agents
Christopher Bunick, MD, PhD
Skirting Steroids in AD: Dangers and Side Effects of Steroid Exposure in Treatment of AD
Peter Lio, MD
Updated Guidelines for Pediatric Atopic Dermatitis Robert Sidbury, MD, MPH
JAK Inhibitors for Pediatric Atopic Dermatitis
Robert Sidbury, MD, MPH
Biologics vs JAK Inhibitors for Atopic Dermatitis Christopher Bunick, MD, PhD, and Brett King, MD, PhD
New Topicals for AD and Psoriasis
Peter Lio, MD
2021
New Pediatric Drugs
Biologics in Dermatology
Clinical Update: Novel Agents for the Long‐Term Management of Moderate‐to‐Severe Atopic Dermatitis
Current Landscape in the Treatment of Atopic Dermatitis
Tapinarof: Therapeutic AhR Modulating Agent (TAMA)
2020
Skin of Color Symposium
Challenging Cases in Atopic Dermatitis
Therapeutics on the Horizon
Recent Advances in Moderate to Severe AD: JAK Inhibitors
Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?
This is the sixth episode of our ongoing “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?”, featuring Beth Sweney, PA-C discusses the following topics:
- Challenges in achieving treatment targets in AD
- Therapeutic inertia and clinical implications of inadequate response
- Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD
- Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies
Podcast also available on:
Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?
This is the fifth episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?”, featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics:
- Mechanistic differences between JAKi and biologics for treatment of AD
- Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics
- Pearls for prescribing JAKi to AD patients
- Strategies for choosing JAKi vs biologics based on safety and patient factors
Podcast also available on:
Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy
This is the fourth episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy”, featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics:
- Identifying ideal candidates for oral JAK inhibitor therapy
- Steps to initiate therapy and onboard new patients
- How to manage side effects and maintain adherence to treatment
- Case examples and real-world data
Podcast also available on:
The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence
This is the third episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence”, featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:
- Overall impact of atopic dermatitis on patients’ quality of life
- Overview of the role of various existing treatments for AD and expert guidelines
- Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab
- Defining treatment success and best practices for treatment selection
Podcast also available on:
JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis
This is the second episode of our new “Program on JAK Inhibitors for Atopic Dermatitis” series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, “JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis”, featuring expert dermatologist Dr. James Song, MD, discusses the following topics:
- Short- and long-term efficacy and safety data for JAK inhibitor therapies
- New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD
- Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies
- Emerging clinical developments and what’s coming next in JAK inhibitor research
Podcast also available on:
The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors
This is the first episodes of a new series hosted by expert dermatologist Dr.
Christopher Bunick who will be discussing the evolving role of JAK inhibitor
therapies in the management of atopic dermatitis (AD). This episode, “The
Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors”,
featuring expert dermatologist Dr. John Koo, discusses the following topics:
- Understanding atopic dermatitis as a spectrum disorder, phenotypes and
endotypes, and heterogeneity of atopic disease - Summarizing JAK inhibitor therapies, including clinical safety and efficacy
and mechanism of action - Comparison of JAKi to biologics and traditional systemic agents, and the
evolving role of JAKi in treatment of AD
Podcast also available on:
Linda Stein Gold,
MD
Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis
Linda Stein Gold, MD, Chair of the CME Symposium “Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis” at SBS 2021, leads a panel discussion with Peter Lio, MD and Andrew Alexis, MD, to share clinical pearls and key takeaways about the management of atopic dermatitis.
Podcast also available on:
Fernanda Schmidt,
MD
Evolving Paradigms in Atopic Dermatitis
Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:
- What are the inside-out and outside-in mechanisms of AD?
- Is there a difference between these mechanisms across the age spectrum – from children to adults?
- Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?
Podcast also available on:
Leon Kircik,
MD
Perspectives on Emerging AD Therapies
Leon Kircik, MD discusses the potential role of emerging AD treatments, including:
- Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
- What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
- Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
- In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?
Podcast also available on:
Lawrence Schachner,
MD
Pearls on Integrating Newer AD Treatments
Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:
- How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
- Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
- How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?
Podcast also available on:
Neal Bhatia,
MD
The Promise of JAK Inhibitors in AD
Neal Bhatia, MD discusses the potential role of JAKis in AD, including:
- What changes would JAKis bring to the treatment of AD in the near future?
- What are some JAKis currently under clinical development for AD?
- Do you foresee that JAKis will play a role in both adult and pediatric AD?
- Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
- What are the long-term implications for dermatology practice?
Podcast also available on:
Patient Resources
Atopic dermatitis (AD), sometimes called eczema, is one of many allergic skin conditions that affects children and adults. AD is a chronic and often relapsing disease which presents as a dry, scaly rash that be accompanied by redness, itching, oozing, cracking or bleeding. People with AD are more likely to develop another atopic condition and are more prone to infections and mental health conditions. The management of AD involves keeping the skin clean and moisturized, eliminating irritants, using topical and oral medications, and avoiding flares and infections.
